Key facts
- TETmedical’s last known valuation is $10.5M (Feb 2024).
- It has raised $4.0M across 2 recorded rounds; the latest was Seed Round ($3.5M) in Jun 2026.
- Notable investors include National Institutes of Health, Bantam Group, New York Ventures, Launchpad Venture Group, SideCar Angels — 11 tracked in total.
- TETmedical has filed 1 Form D with the SEC, most recently Jun 2023 ($2.5M sold to 70 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for TETmedical
Funding rounds
2 roundsAbout TETmedical
Developer of an in vitro diagnostic nanomedicine platform designed for clinical diagnostic use. The company's platform uses tethered enzymes bound to silica nanoparticles to form a stable molecular system capable of rapid catalytic reactions, high analytical sensitivity, and compatibility with standard laboratory plate readers, enabling hospital and emergency department diagnostics to support time-sensitive disease assessment, biomarker detection across proteins, enzymes, viruses, and microRNAs, and informed clinical decision making with reduced uncertainty.
- Sector
- Healthcare
- HQ
- Fair Haven, NJ, United States
- Founded
- 2021
- Employees
- 7
- Website
- tetmedical.com/
- Ownership
- Privately Held (backing)
TETmedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TETmedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TETmedical in its N-PORT filings yet. We sweep new filings monthly.